Encompass Health (EHC) CEO Mark Tarr sells 173,148 shares in open-market trades

Rhea-AI Filing Summary

Encompass Health Corp President & CEO Mark J. Tarr reported two open-market sales of Encompass Health common stock on 2026-08-10. He sold 171,569 shares at a weighted average price of $125.46 and 1,579 shares at a weighted average price of $126.06, with each sale executed in multiple transactions within specified price ranges described in the footnotes. Post-transaction share holdings are not reported in this filing.

Insider Trade Summary

Net Seller: 173,148 shares

Net Sell 2 txns

Insider Tarr Mark J

Role President & CEO

Sold 173,148 shs ($21.72M)

Type	Security	Shares	Price	Value
Sale	Encompass Health Common Stock F1	171,569	$125.46	$21.53M
Sale	Encompass Health Common Stock F2	1,579	$126.06	$199K

Holdings After Transaction: Encompass Health Common Stock — 267,814 shares (Direct)

Footnotes (2)

1. F1. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.92, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
2. F2. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.93 to $126.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

Key Figures

Shares sold (block 1): 171,569 shares Price block 1 range: $124.93–$125.92 per share Shares sold (block 2): 1,579 shares +2 more

5 metrics

Shares sold (block 1) 171,569 shares Non-derivative sale at weighted average price of $125.46 on 2026-08-10

Price block 1 range $124.93–$125.92 per share Multiple transactions comprising the 171,569-share sale

Shares sold (block 2) 1,579 shares Non-derivative sale at weighted average price of $126.06 on 2026-08-10

Price block 2 range $125.93–$126.22 per share Multiple transactions comprising the 1,579-share sale

Total shares sold 173,148 shares Aggregate of reported non-derivative sales on 2026-08-10

Key Terms

weighted average price, multiple transactions, open market or private transaction

3 terms

weighted average price financial

"This per share price is a weighted average price. These shares were sold in multiple"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging from"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider trading did Encompass Health (EHC) report for Mark J. Tarr?

Encompass Health reported that President & CEO Mark J. Tarr sold 173,148 shares of common stock on 2026-08-10 in two open-market transactions at weighted average prices of $125.46 and $126.06 per share.

How many Encompass Health (EHC) shares did the CEO sell in each transaction?

On 2026-08-10, CEO Mark J. Tarr sold 171,569 shares at a weighted average of $125.46 and 1,579 shares at a weighted average of $126.06, according to the reported Form 4 transactions.

What price range applied to the 171,569 Encompass Health (EHC) shares sold?

The $125.46 weighted average price for the 171,569 shares reflects multiple trades executed between $124.93 and $125.92, as disclosed, with full trade-by-trade details available on request from the reporting person.

What price range applied to the additional 1,579 Encompass Health (EHC) shares sold?

The $126.06 weighted average price for the 1,579 shares reflects multiple trades executed between $125.93 and $126.22, as stated, with the reporting person undertaking to provide detailed pricing information upon request.

Were the Encompass Health (EHC) CEO stock sales under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a plan. The transactions are reported as open-market sales, and no footnote states they were executed under a pre-arranged trading plan.

Does the Form 4 state Mark J. Tarr’s Encompass Health (EHC) holdings after these sales?

The reported transactions list shares sold but do not disclose total shares held by Mark J. Tarr following the sales; the post-transaction ownership fields are left blank in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 02:47 PM Accepted by SEC EDGAR 08/11/2026 - 02:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tarr Mark J

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM ALABAMA 35242

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	08/10/2026		S		171,569	D	$125.46(1)	269,393	D
Encompass Health Common Stock	08/10/2026		S		1,579	D	$126.06(2)	267,814	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.92, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

2. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.93 to $126.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

Remarks:

	/s/ Patrick Darby, attorney-in-fact for Mark J. Tarr	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)